118 results about "Isosorbide dinitrate" patented technology

The invention describes novel nitrosated and / or nitrosylated nebivolol, novel nitrosated and / or nitrosylated metabolites of nebivolol and novel compositions comprising at least one nitrosated and / or nitrosylated nebivolol and / or at least one nitrosated and / or nitrosylated metabolite of nebivolol, and, optionally, at least one nitric oxide donor and / or at least one antioxidant or a pharmaceutically acceptable salt thereof, and / or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and / or at least one nitrosated compound used to treat cardiovascular diseases. The invention also provides novel compositions comprising nebivolol and / or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and / or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and / or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and / or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and / or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and / or preventing Raynaud's syndrome; and for treating and / or preventing cardiovascular diseases or disorders.

A process for preparing the isosorbide mononitrate from sorbitol includes dewatering sorbitol by p-methylphenyl sulfonic acid to obtain anhydrosorbitol, protecting by acetic oxide under existance of N,N-dimethylaminopyridine, nitrating by nitric acid / acetic oxide / acetic acid system, and removing protection by potassium carbonate-methanol system. It can be used to treat angina pectoris.

The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and / or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays; (e) reducing the number of hospital admissions for heart failure; and (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

The invention relates to an isosorbide mononitrate sustained-release pellet, and an isosorbide mononitrate quick-release and sustained-release pellet capsule adopting it. The sustained-release film of the sustained-release pellet adopts Eurdragit RS 30D as a film forming material, the core of the sustained-release pellet contains high-expansibility sodium carboxymethyl starch and a pharmaceutically-acceptable excipient commonly used for sustained-release pellets, and optimally, the excipient is microcrystalline cellulose, wherein the weight percentage of sodium carboxymethyl starch in the core of the sustained-release pellet is 5-20%. The sustained-release film of the sustained-release pellet includes the Eurdragit RS 30D, a plasticizer triethyl citrate and an anti-adherent talcum powder, the optimal ratio of the Eurdragit RS 30D to triethyl citrate to the talcum powder is 30:3:4, and the optimal coating weight gain is 19-38%. The core will obviously expand after absorbing water because of the containment of sodium carboxymethyl starch highly expanding after contacting with water, so the sustained-release film is stretched, the thickness of the film is thinned, the apertures of water-pervious micro-pores are increased, the permeability is good, and the permeability decrease caused by film ageing is compensated, thereby the middle and later stage release speed is basically constant, the last stage residue is small, and a stable release performance is always maintained prior to the expiration date.

The invention discloses a compound isosorbide mononitrate aspirin sustained-release capsule preparation. The compound isosorbide mononitrate aspirin sustained-release capsule preparation is characterized by comprising an isosorbide mononitrate sustained-release capsule preparation and an aspirin enteric-coated preparation, wherein the isosorbide mononitrate sustained-release capsule preparation contains 40-80 parts by weight of isosorbide mononitrate and comprises an immediate-release pellet with 30 percent of isosorbide mononitrate and a sustained-release pellet with 70 percent of isosorbide mononitrate, and the aspirin enteric-coated preparation contains 50-90 parts by weight of aspirin. The invention also provides a preparation method of the compound capsule preparation. With the adoption of the compound isosorbide mononitrate aspirin sustained-release capsule preparation, the curative effects are better improved, the adverse reaction due to stimulation from the aspirin to a gastric mucosa is better reduced, and meanwhile, the isosorbide mononitrate can also satisfy the requirement of stable release in a stomach.

The invention belongs to the technical field of Western medicine preparations, and particularly provides an isosorbide mononitrate sustained release tablet and a preparation method thereof. Accordingto the prescription, the sustained release tablet comprises isosorbide mononitrate, lactose, sustained release materials, microcrystalline cellulose, a glidant and a lubricant. An isosorbide mononitrate mixed powder prepared by a special preparation process according to the formula has good fluidity and is suitable for direct tablet compression, and the prepared sustained release tablet is good instability and better in sustained release effect.

The invention provides an emulsion-type paraffin remover, and a preparation method and application thereof. The paraffin remover is prepared from the following components in percentage by volume: 55-60% of oily solvent, 0.5-3% of surfactant and the balance of water, wherein the surfactant is sodium dodecyl benzene sulfonate and / or isosorbide dinitrate laurate. The paraffin remover is simple in formula, on the one hand, the surfactant adopted by the paraffin remover can make a system to form stable emulsion at the normal temperature, and the stable time is long; and on the other hand, when theparaffin remover is added into a formation and the temperature rises, the system can rapidly break the emulsion, and thus an organic solvent can exert a paraffin dissolving effect with the greater efficacy. The surfactant adopted by the paraffin remover can further form a layer of water film on the surface of an oil pipe, so that the effects of decreasing the depositing quantity of oil well paraffin and prolonging the paraffin removing period are achieved.

The invention belongs to the field of medicine and particularly relates to an application of a pharmaceutical composition taking isosorbide mononitrate and ivabradine as active pharmaceutical ingredients in preparation of medicine for treating diastolic heart failure. By conformation through a lot of pharmacology experiment, the isosorbide mononitrate and the ivabradine can obviously improving heart diastolic function of patients with diastolic heart failure, and remarkable synergistic effect is achieved in the aspect of treating the diastolic heart failure. The pharmaceutical composition is obvious in treating effect and little in side effects in treating the diastolic heart failure, and is quite good in medical application prospect.